Tags

Type your tag names separated by a space and hit enter

Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study.
Br J Haematol. 2016 Oct; 175(2):265-274.BJ

Abstract

We conducted a prospective, multicentre study to confirm the feasibility of haplo-identical transplantation in treatment of severe aplastic anaemia (SAA) as salvage therapy, by analysing the outcomes of 101 patients who received haplo-identical transplantation between June 2012 and October 2015. All cases surviving for more than 28 d achieved donor myeloid engraftment. The median time for myeloid engraftment was 12 (range, 9-25) days and 15 (range, 7-101) days for platelets, with a cumulative platelet engraftment incidence of 94·1 ± 0·1%. With a median follow-up of 18·3 (3·0-43·6) months, recipients from haplo-identical transplantation had more cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD, 33·7% vs. 4·2%, P < 0·001), more chronic GVHD (22·4% vs. 6·6%, P = 0·014) at 1 year, but similar grade III-IV aGVHD (7·9% vs. 2·1%, P = 0·157), 3-year estimated overall survival (OS, 89·0% vs. 91·0%, P = 0·555) and failure-free survival (FFS, 86·8% vs. 80·3%, P = 0·659) when compared with 48 patients who received contemporaneous transplantation from matched related donors. Multivariate analysis showed no significant difference in engraftment and survival between the two cohorts. Both OS and FFS for the entire population correlated significantly with grades III-IV aGVHD. In conclusion, haplo-identical transplantation is a feasible choice for SAA with favourable outcomes.

Authors+Show Affiliations

Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.Guangzhou First People's Hospital, Guangzhou, China.The First affiliated Hospital of Soochow University, Soochow, China.Changhai Hospital affiliated to Second Military Medical University, Shanghai, China.The First Hospital of Jilin University, Changchun, China.The First affiliated Hospital of Xinjiang Medical University, Urumchi, China.Lanzhou Military Area General Hospital, Lanzhou, China.Xinqiao Hospital affiliated to Third Military Medical University, Chongqing, China.Nanfang Hospital affiliated to Southern Medical University, Guangzhou, China.Xiehe Hospital affiliated to Huazhong University of Science and Technology, Wuhan, China.Shandong Provincial Hospital, Jinan, China.Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China. xjhrm@medmail.com.cn. Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China. xjhrm@medmail.com.cn. Peking-Tsinghua Centre for Life Sciences, Beijing, China. xjhrm@medmail.com.cn.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

27352174

Citation

Xu, Lan-Ping, et al. "Haplo-identical Transplantation for Acquired Severe Aplastic Anaemia in a Multicentre Prospective Study." British Journal of Haematology, vol. 175, no. 2, 2016, pp. 265-274.
Xu LP, Wang SQ, Wu DP, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175(2):265-274.
Xu, L. P., Wang, S. Q., Wu, D. P., Wang, J. M., Gao, S. J., Jiang, M., Wang, C. B., Zhang, X., Liu, Q. F., Xia, L. H., Wang, X., & Huang, X. J. (2016). Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. British Journal of Haematology, 175(2), 265-274. https://doi.org/10.1111/bjh.14225
Xu LP, et al. Haplo-identical Transplantation for Acquired Severe Aplastic Anaemia in a Multicentre Prospective Study. Br J Haematol. 2016;175(2):265-274. PubMed PMID: 27352174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. AU - Xu,Lan-Ping, AU - Wang,Shun-Qing, AU - Wu,De-Pei, AU - Wang,Jian-Min, AU - Gao,Su-Jun, AU - Jiang,Ming, AU - Wang,Cun-Bang, AU - Zhang,Xi, AU - Liu,Qi-Fa, AU - Xia,Ling-Hui, AU - Wang,Xin, AU - Huang,Xiao-Jun, Y1 - 2016/06/28/ PY - 2016/03/13/received PY - 2016/05/04/accepted PY - 2016/6/29/pubmed PY - 2017/5/16/medline PY - 2016/6/29/entrez KW - haematopoietic stem cell transplantation KW - haploidentical KW - severe aplastic anaemia SP - 265 EP - 274 JF - British journal of haematology JO - Br. J. Haematol. VL - 175 IS - 2 N2 - We conducted a prospective, multicentre study to confirm the feasibility of haplo-identical transplantation in treatment of severe aplastic anaemia (SAA) as salvage therapy, by analysing the outcomes of 101 patients who received haplo-identical transplantation between June 2012 and October 2015. All cases surviving for more than 28 d achieved donor myeloid engraftment. The median time for myeloid engraftment was 12 (range, 9-25) days and 15 (range, 7-101) days for platelets, with a cumulative platelet engraftment incidence of 94·1 ± 0·1%. With a median follow-up of 18·3 (3·0-43·6) months, recipients from haplo-identical transplantation had more cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD, 33·7% vs. 4·2%, P < 0·001), more chronic GVHD (22·4% vs. 6·6%, P = 0·014) at 1 year, but similar grade III-IV aGVHD (7·9% vs. 2·1%, P = 0·157), 3-year estimated overall survival (OS, 89·0% vs. 91·0%, P = 0·555) and failure-free survival (FFS, 86·8% vs. 80·3%, P = 0·659) when compared with 48 patients who received contemporaneous transplantation from matched related donors. Multivariate analysis showed no significant difference in engraftment and survival between the two cohorts. Both OS and FFS for the entire population correlated significantly with grades III-IV aGVHD. In conclusion, haplo-identical transplantation is a feasible choice for SAA with favourable outcomes. SN - 1365-2141 UR - https://www.unboundmedicine.com/medline/citation/27352174/Haplo_identical_transplantation_for_acquired_severe_aplastic_anaemia_in_a_multicentre_prospective_study_ L2 - https://doi.org/10.1111/bjh.14225 DB - PRIME DP - Unbound Medicine ER -